SHL Medical exhibits at CPHI Japan for the first time
SHL Medical is pleased to announce our participation in CPHI Japan 2023 for the first time. The hybrid event will be held in Tokyo, Japan on April 19-21, where SHL will be exhibiting at Stand 5G-25. CPHI Japan will also provide virtual networking opportunities between April 5-28.
With one of the largest pharmaceutical industries in the world, Japan presents a unique business opportunity in combination product development. In fact, several of SHL customers’ combination products have been available in Japan for more than a decade. Through CPHI Japan, SHL further fortifies our presence in the Japanese market. We are excited to meet and interact with leading pharmaceutical companies and emerging biotechnology startups within the region. We are eager to stimulate meaningful discussions on the latest innovations in the drug delivery industry.
The Molly® modular platform autoinjectors will remain to be one of the highlights of SHL’s exhibition. Since its introduction in 2016, Molly has set an impressive track record with 17 combination product approvals under its belt. Its modular technology makes Molly an ideal solution for autoinjector combination product requirements in scalable production, assembly, and final product testing. Backed by a solid infrastructure built through decades of experience in device development and commercialization, the Molly platform devices continue to enjoy their successful figure as one of the most versatile offerings in SHL’s portfolio.
SHL’s booth will also feature the Maggie® autoinjectors. Available in 3.0 mL and 5.0 mL variations, Maggie is a cartridge-based solution developed with pre-installed Needle Isolation Technology (NIT®). NIT offers the added flexibility of a wide range of needle lengths and gauges not readily available in pre-filled syringes with staked needles. With this technology, SHL seeks to provide a more convenient injection experience as NIT eliminates the need for users to manually attach the needle. Autoinjectors integrating the NIT cannula system have already enjoyed considerable commercial success on the market since its launch in 2017. SHL has also recently published an article that outlines the evolving trends in the subcutaneous delivery of parenteral formulations, including larger administration volumes.
Covering digital health and connectivity, InsulCheck® DOSE by Innovation Zed will also be featured in SHL’s booth. Born out of SHL’s Innovation Partnership program, this reusable connected add-on device for pen injectors was co-developed with Innovation Zed. The device technology is manufactured by our subsidiary, SHL Technologies. The device uses Bluetooth® technology to automatically transfer injection time and dialed dose volume to a smartphone application. It also features a customizable sleeve and a built-in firmware over-the-air (FOTA) capability. Recently, InsulCheck DOSE successfully secured CE mark, expanding its support to insulin pen users within the diabetes population in Europe.
Aside from exploring our device offerings, visitors can gain additional information from our team members onsite regarding SHL’s end-to-end services. We boast a comprehensive set of in-house capabilities and expertise that can guide our partners throughout a product’s lifecycle – from planning, development, mass production, to post-production services.
Contact us today to reserve a meeting with our team.
Where : Tokyo Big Sight, Tokyo, Japan | Stand 5G-25
When : April 19-21
